The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT03304288 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

168

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Rituximab
DRUG: All-trans retinoic acid

Sponsor

Peking University People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]